89BIO (ETNB) Competitors $10.10 +0.37 (+3.78%) Closing price 03:59 PM EasternExtended Trading$10.10 +0.00 (+0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETNB vs. TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, PCVX, ADMA, and KRYSShould you be buying 89BIO stock or one of its competitors? The main competitors of 89BIO include TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. 89BIO vs. Its Competitors TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics Krystal Biotech 89BIO (NASDAQ:ETNB) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Is ETNB or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to 89BIO's net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets 89BION/A -81.44% -70.17% TG Therapeutics 10.13%18.88%7.05% Which has preferable earnings and valuation, ETNB or TGTX? TG Therapeutics has higher revenue and earnings than 89BIO. 89BIO is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89BION/AN/A-$367.08M-$3.38-2.99TG Therapeutics$329M17.48$23.38M$0.24150.94 Which has more risk & volatility, ETNB or TGTX? 89BIO has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Does the media prefer ETNB or TGTX? In the previous week, TG Therapeutics had 6 more articles in the media than 89BIO. MarketBeat recorded 11 mentions for TG Therapeutics and 5 mentions for 89BIO. TG Therapeutics' average media sentiment score of 0.83 beat 89BIO's score of 0.63 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 89BIO 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ETNB or TGTX? 89BIO currently has a consensus price target of $26.43, suggesting a potential upside of 161.72%. TG Therapeutics has a consensus price target of $40.80, suggesting a potential upside of 12.63%. Given 89BIO's stronger consensus rating and higher probable upside, analysts plainly believe 89BIO is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89BIO 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do insiders & institutionals hold more shares of ETNB or TGTX? 58.6% of TG Therapeutics shares are owned by institutional investors. 2.8% of 89BIO shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTG Therapeutics beats 89BIO on 12 of the 15 factors compared between the two stocks. Get 89BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.47B$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-2.9921.2626.2019.89Price / SalesN/A279.34415.50166.23Price / CashN/A41.8936.4957.06Price / Book3.027.508.055.39Net Income-$367.08M-$55.05M$3.15B$248.50M7 Day Performance3.46%2.49%1.92%2.96%1 Month Performance-0.12%7.40%4.90%6.02%1 Year Performance32.87%5.42%35.95%20.44% 89BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89BIO1.9397 of 5 stars$10.10+3.8%$26.43+161.7%+25.4%$1.47BN/A-2.9940Positive NewsTGTXTG Therapeutics3.7452 of 5 stars$36.56+1.5%$40.80+11.6%+95.0%$5.80B$329M152.33290GRFSGrifols4.1197 of 5 stars$8.37-4.6%$10.30+23.1%+43.3%$5.75B$7.81B7.1523,822Analyst DowngradeLNTHLantheus4.4423 of 5 stars$80.81+2.0%$130.50+61.5%-0.7%$5.59B$1.53B22.96700Positive NewsTLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.54B$516.72M0.00N/AGap DownHigh Trading VolumeNUVLNuvalent3.7087 of 5 stars$75.98+1.3%$115.50+52.0%+3.3%$5.46BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.6726 of 5 stars$101.65+1.0%$172.33+69.5%+27.1%$5.01B$385.69M-17.62380Analyst RevisionAKROAkero Therapeutics3.6155 of 5 stars$54.03-0.3%$82.50+52.7%+122.0%$4.31BN/A-27.7130PCVXVaxcyte1.7882 of 5 stars$33.25+1.2%$136.50+310.5%-57.2%$4.29BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.0895 of 5 stars$17.87+0.7%$27.67+54.8%+54.8%$4.27B$426.45M21.02530KRYSKrystal Biotech4.6181 of 5 stars$137.92+4.1%$211.13+53.1%-23.7%$3.99B$290.52M33.15210Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETNB) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89BIO Please log in to your account or sign up in order to add this asset to your watchlist. Share 89BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
